Marianne Velasco - Genomma Lab Global HR
| GNMLF Stock | USD 1.27 0.00 0.00% |
Insider
Marianne Velasco is Global HR of Genomma Lab Internacional
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Damon Terrill | Alpha Teknova | 53 | |
| Luiz Clavis | Hypera SA | N/A | |
| Joao Aguilar | Hypera SA | N/A | |
| Lisa McCann | Alpha Teknova | 42 | |
| Cecilia Coupland | Orexo AB | 47 | |
| Adam Mostafa | Cumberland Pharmaceuticals | 44 | |
| Cindy Patton | Cumberland Pharmaceuticals | 71 | |
| A MBA | Cumberland Pharmaceuticals | 66 | |
| Mitchell MBA | Petros Pharmaceuticals | 60 | |
| Adalmario Couto | Hypera SA | N/A | |
| Mauricio Christovam | Hypera SA | N/A | |
| Robert Ronn | Orexo AB | 47 | |
| Albert Bolles | Lifecore Biomedical | 66 | |
| Matthew Lowell | Alpha Teknova | 54 | |
| Sonny Newman | C21 Investments | N/A | |
| Dennis Urbaniak | Orexo AB | 54 | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
| Eric Shoemaker | C21 Investments | N/A | |
| Patrick Bilbo | Organogenesis Holdings | 62 | |
| Brian Grow | Organogenesis Holdings | 48 | |
| Hlio Segouras | Hypera SA | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 |
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Efran Crdova, Deputy Sec | ||
| Engineer Galland, Exec CFO | ||
| Marianne Velasco, Global HR | ||
| Mximo Juda, Advisor | ||
| L Porres, Legal Officer | ||
| Daniel Neria, Head Relations | ||
| Jorge Valderrama, Chief Officer | ||
| Juan Sparvieri, Ex COO | ||
| Alejandro Patio, Media, Relations |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Genomma Pink Sheet
Genomma Lab financial ratios help investors to determine whether Genomma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomma with respect to the benefits of owning Genomma Lab security.